www.diagnosticimaging.com Open in urlscan Pro
76.76.21.22  Public Scan

Form analysis
2 forms found in the DOM

<form style="padding:6px;width:100%" class="form-inline"><input type="text" style="width:20%;flex-grow:1" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none;width:20%;margin-left:2%"
    type="button" class="btn btn-primary">Search</button></form>

<form style="padding:6px" class="form-inline"><input type="text" style="width:50%;flex-grow:1" placeholder="Search" value="" class="form-control"><button style="background-color:var(--secondary);border:none;width:20%;margin-left:2%" type="button"
    class="btn btn-primary">Search</button></form>

Text Content

Auf dieser Website werden Daten wie Cookies gespeichert, um wichtige Funktionen
der Website sowie Marketing, Personalisierung und Analyse zu ermöglichen. Sie
können Ihre Einstellungen jederzeit ändern oder die Standardeinstellungen
übernehmen. Cookie-Richtlinie
   
 * Marketing
   
   
 * Personalisierung
   
   
 * Analyse
   

Speichern Alle akzeptieren


Search
Spotlight
RSNA 2021 CoverageCTImage IQ Quiz
RSNA 2021 CoverageCTImage IQ Quiz
Topics
View MoreMRICTUltrasoundMammographyX-RayFacility ManagementView More
MRICTUltrasoundMammographyX-RayFacility ManagementView More
Neurology CTOncology Ultrasound
News
All NewsBlogs
All NewsBlogs
Media
Around the Practice Between the LinesImage IQMedical World NewsPodcastsVideos
Around the Practice Between the LinesImage IQMedical World NewsPodcastsVideos
Conferences
Conference CoverageConference Listing
Conference CoverageConference Listing
DI Executive
Resources
CME/CEE-booksEducationPartnersSponsored
CME/CEE-booksEducationPartnersSponsored
Subscribe
eNewsletterPrint Subscription
eNewsletterPrint Subscription
Search



 * Advertise
 * Contact Us
 * Editorial
 * Editorial Board
 * Do Not Sell My Personal Information
 * Privacy
 * Terms and Conditions

 * 
 * 

© 2022 MJH Life Sciences and Diagnostic Imaging. All rights reserved.


Spotlight
 * RSNA 2021 Coverage
 * CT
 * Image IQ Quiz

TopicsSee All >
 * MRI
 * CT
 * Ultrasound
 * Mammography
 * X-Ray
 * Facility Management
 * View More

Neurology CTSee All >
Oncology UltrasoundSee All >
 * Advertise
 * Contact Us
 * Editorial
 * Editorial Board
 * Do Not Sell My Personal Information
 * Privacy
 * Terms and Conditions
 * 

 * 

© 2022 MJH Life Sciences™ and Diagnostic Imaging. All rights reserved.


COULD A DEEP LEARNING SYSTEM FACILITATE THE DIAGNOSIS OF TYPE 2 DIABETES ON
ABDOMINAL CT?

April 7, 2022
Jeff Hall






Employing a deep learning system for pancreatic segmentation, researchers found
that intrapancreatic fat percentage and pancreatic fractal dimension were among
the key predictors for type 2 diabetes mellitus in a multivariable analysis.



In a newly published retrospective study that incorporated deep learning
technology and involved nearly 9,000 patients, researchers found that abdominal
computed tomography (CT) biomarkers, such as pancreatic CT attenuation and
visceral fat, were associated with the diagnosis of type 2 diabetes mellitus.

In the study of 8,992 patients (including 572 patients with type 2 diabetes),
the study authors utilized a deep learning system to segment the pancreas and
provide measurements of pancreas fractal dimension, CT attenuation and fat
content. Other assessed biomarkers included visceral fat, liver CT attenuation
and atherosclerotic plaque, according to the study, which was published in
Radiology.

The researchers found that patients with diabetes had lower average pancreatic
CT attenuation (mean of 18.74 HU vs. 29.99 HU) and greater visceral fat volume
(mean of 235 mL vs. 130.9 mL) in comparison to those without diabetes. The study
authors also noted that greater duration of diabetes also corresponded with a
progressive decrease in pancreatic attenuation.

Pointing to the findings from the multivariable analysis, the study authors said
the CT-derived factors had “considerable predictive power.” Five of the six
optimal factors for predicting type 2 diabetes were CT measures of total and
eroded volumes of intrapancreatic fat percentage, pancreas fractal dimension,
average liver attenuation and plaque severity between the L1 and L4 vertebra
levels.

“This proves the final model’s ability to discern patients with type 2 diabetes
before and after diagnosis from participants without diabetes,” wrote Ronald M.
Summers, MD, a senior investigator and director of the Imaging Biomarkers and
Computer-Aided Diagnosis Laboratory with the National Institutes of Health (NIH)
Clinical Center in Bethesda, Md., and colleagues.

The study authors also noted that machine-to-person variability for the deep
learning technology was similar to interobserver variability.

In regard to the limitations of the retrospective study, the authors
acknowledged that the timing of the CT scans varied considerably, ranging
between 5,055 days prior to diabetes diagnosis to 4,822 days after a patient had
been diagnosed. They also noted that disease stage could not be determined and
that the final study model did not include factors such as family history,
hypertension, and blood glucose levels.

While noting that further improvement is necessary when it comes to the clinical
use of automated pancreas segmentation, Dr. Summers and colleagues said that CT
biomarkers may have the potential to facilitate earlier diagnosis of type 2
diabetes.






Related Content:

CTWomen's Health CT
Study Finds Over Half of Patients with COVID-19 Pneumonia Have Pulmonary
Abnormalities One Year Later
What Does the Future of Certification Look Like?
Fracture Detection: Study Suggests AI Assessment May Be as Effective as
Clinician Assessment
Related Article >>>

--------------------------------------------------------------------------------


x